These findings reveal a novel pathway through which apoA-I ameliorates MASLD by modulating the gut microbiota and increasing PPA levels, which activate a hepatic lipolysis cascade. The gene discussed is APOA1; the disease is metabolic dysfunction-associated steatotic liver disease.